This company has been marked as potentially delisted and may not be actively trading. NASDAQ:APTO Aptose Biosciences (APTO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesInsider TradesTrendsBuy This Stock About Aptose Biosciences Stock (NASDAQ:APTO) Get Aptose Biosciences alerts:Sign Up Key Stats Today's Range$1.71▼$1.7150-Day Range$1.71▼$6.8652-Week Range$1.35▼$50.10VolumeN/AAverage Volume227,964 shsMarket Capitalization$3.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada. Read More Receive APTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APTO Stock News HeadlinesAptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi PharmaceuticalApril 30, 2026 | markets.businessinsider.comAptose Hanmi Acquisition Closing Delayed Pending Korean ApprovalsApril 30, 2026 | tipranks.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 5 at 1:00 AM | Brownstone Research (Ad)Aptose Biosciences, Inc.: Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year ...April 1, 2026 | finanznachrichten.deAptose Biosciences: Q4 Earnings SnapshotApril 1, 2026 | chron.comAptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate HighlightsMarch 31, 2026 | financialpost.comFAptose Clarifies CEO Employment Terms and Compensation ObligationsMarch 23, 2026 | tipranks.comLeading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of ArrangementMarch 23, 2026 | financialpost.comFSee More Headlines APTO Stock Analysis - Frequently Asked Questions How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (NASDAQ:APTO) issued its earnings results on Thursday, August, 8th. The biotechnology company reported ($12.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($17.40) by $4.50. When did Aptose Biosciences' stock split? Aptose Biosciences shares reverse split before market open on Wednesday, February 26th 2025.The 1-30 reverse split was announced on Tuesday, February 18th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptose Biosciences investors own include Digital Turbine (APPS), Okta (OKTA), Canoo (GOEV), CrowdStrike (CRWD) and NVIDIA (NVDA). Company Calendar Last Earnings8/08/2024Today5/05/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:APTO CIK882361 Webwww.aptose.com Phone858-926-2730Fax905-234-2120Employees31Year Founded2014Profitability EPS (Trailing Twelve Months)($89.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-5,683.22% Return on Assets-300.44% Debt Debt-to-Equity RatioN/A Current Ratio1.05 Quick Ratio1.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.19) per share Price / Book-9.00Miscellaneous Outstanding Shares2,141,000Free Float63,446,000Market Cap$3.66 million OptionableNo Data Beta1.04 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:APTO) was last updated on 5/5/2026 by MarketBeat.com Staff. From Our PartnersIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredThe $1.75T "Backdoor" ticker (NOT Starlink)When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...Behind the Markets | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
